Next Phase Newsletter

A global investment firm founded in 2005 has about $300 AUM and invests in a wide variety of sectors, with healthcare being one of the major areas of interest. The firm can invest anywhere from $0.25 – 25M, depending on the company’s stage of development. Currently, the firm is primarily investing in USA-based opportunities.

The firm is opportunistic in terms of technology and indication and will consider all types of technologies with high growth potential, in therapeutics, medical devices, diagnostics, and digital health sectors. The firm is the largest stakeholder in a late-clinical-stage therapeutics company, but the firm is certainly open to pre-clinical therapeutics companies as well.

The firm no specific management team requirements. The firm often leads investment rounds, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Hangzhou, China  makes early-growth stage investments, preferably in series A and B, but will consider series C. The firm typically invests USD 1-30 million per company. The firm prefers to invest in companies based in China, but is open to outstanding Chinese-led companies based in the US and Canada. The firm is actively seeking new investment opportunities.

In the life sciences, the firm currently considers therapeutics and diagnostics in bone/joint diseases, renal diseases, autoimmune disease, cancer, and fibrosis. The firm is especially interested in immunotherapy, gene editing, and stem cell therapy that have preclinical data. Clinical data is desired, but not required.

The firm typically seeks Chinese-led teams with strong technical expertise and industry experience. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm with offices in the West and East Coasts invests in startups in highly regulated industries, including healthcare. The firm is interested in making investments at the seed and early venture stages; seed investments are typically $1-3 million. The firm invests globally.

The firm invests in digital health, and the firm is also interested in investing in early stage therapeutics. In the digital health space, the firm is primarily focused on technologies used by consumers/patients, and prefers to invest in companies that have revenues of at least $1 million or several customers and demonstrated product/market fit. In therapeutics, the firm is interested in preclinical technologies; the firm is open to investing in any therapeutic modality including cell and gene therapies. The firm is interested in oncology, immunology and diabetes, and will consider investing in other indication areas as well; however, antibiotics are not of interest. The firm may also consider investing in novel molecular diagnostics, provided there is a strong scientific component to the technology.

The firm is focused on investing in early stage companies, and typically invests in startups with under 15 staff. The firm focuses on finding the right team and the right science, and is interested in investing in early stage therapeutics in order to fund those companies through proof of concept studies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office, based in New York City, is looking to invest in therapeutics. The firm is most interested in companies that are IND ready through raising funds for Phase IIb clinical trials. The firm is willing to lead or co-invest, and will invest between $100K-$1.5M, depending on the round and the financial needs of the company. Historically, the firm has focused on investing in US and Israel.

The firm is interested primarily in therapeutics technologies. While agnostic to type of therapeutic, and open to most indications, much of the firm’s previous investments have been in oncology, cardiovascular or CNS related indications. The firm will invest as early as IND-ready companies, but no later than companies raising money for Phase IIb trials.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a large Japanese holding company is seeking to foster innovation across the group by investing in and partnering with strategic startups. In principle, the corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/medical is one of the major focus areas of the holding company, and the corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines.

The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with other business arms within the holding company and can also present opportunities to them as appropriate.

The corporate venture arm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. Through the firm’s strategic relationships, the group can help with Japan market entry and clinical trials, among other areas of needed support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital firm formed in 2017 manages 2 funds, a RMB denominated fund and a parallel USD fund. The firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB $30-150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A California-based firm manages two active funds for both early-stage and growth investments. The firm is interested in investing in early-growth stage healthcare companies; the firm primarily invests in North America, but will consider opportunities worldwide. The firm typically makes Series A investments of ~$5-15M and Series B or later stage investments of ~$20-25 million. The firm is generally a lead investor, but will also enter syndicates with other major investors.

The firm is primarily interested in opportunities across digital health, transformational health IT, and biotech. In digital health, the firm focuses on technologies and services used by consumers or by enterprise/employers; in other categories, the firm has spent time, the firm’s interests include computational tools such as drug discovery tools and back-end solutions that can be used by companies in the clinical trial process during development of new drugs or devices. While the firm typically invests in companies that already have revenue, the firm may consider investing in prerevenue companies provided they have proven product-market fit by other means, such as securing key partnerships.

The firm invests primarily in US-based companies, but considers opportunities in other markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.